

### Investor Conference 2023 Q3 Results

Nov 15,2023

### Agenda

- —. 2023 Q3 Financial Results and Business Summary
- —. Operational Outlook
- 三. Q&A



#### **Safe Harbor Notice**

We have made forward-looking statements in the presentation. Our forward-looking statements contain information regarding, among other things, our financial conditions, future expansion plans, and business strategies. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe these expectations and projections are reasonable, such forward-looking statements are inherently subject to risks, uncertainties, and assumptions about us.

We undertake no obligation to publicly update or revise any forward-looking statements, whether due to new information, future events, or otherwise. In light of these risks, uncertainties, and assumptions, the forward-looking events might not occur, and our actual results could differ materially from those anticipated in these forward-looking statements.



# —. 2023 Q3 Financial Results and Business Summary



## Statement of Comprehensive Income (Consolidated)

2022 02

**Amount: NT\$ Thousand** 

2023 Q	2
3,761,152	100.0%
(2,981,988)	
779,164	20.7%
(655,303)	-17.4%
123,861	3.3%
7,854	
131,715	3.5%
99,375	2.6%
97,597	2.6%
\$0.85	
	3,761,152 (2,981,988) 779,164 (655,303) 123,861 7,854 131,715 99,375 97,597

2023 Q3	
3,921,424	100.0%
(3,209,182)	
712,242	18.2%
(635,314)	-16.2%
76,928	2.0%
(13,923)	
63,005	1.6%
35,625	0.9%
53,688	1.4%
\$0.47	

2022 Q3	
4,093,050	100.0%
(3,199,645)	
893,405	21.8%
(670,988)	-16.4%
222,417	-5.4%
37,119	
259,536	6.3%
200,020	4.9%
194,205	4.7%
<b>\$1.69</b>	

2022 03

(a) EPS was calculated based on total Weighted -average Outstanding shares (thousand shares)

114,488

114,488

114,488



## Statement of Comprehensive Income (Consolidated)

**Amount: NT\$ Thousand** 

**Net sales** 

Cost of Good Sold

**Gross Margin** 

**Operating Expenses** 

**Operating Income** 

Non-operating Income and Expenses

**Profit(Loss) before Tax** 

**Net Income** 

**Shareholders of the company** 

EPS(NT\$)(a)

**YTD** 2023 Jan.-Sep. 11,502,617 100.0% (9,176,083)2,326,534 20.2% (1,926,638)-16.7% 399,896 3.5% (31,878)368,018 3.2% 261,151 2.3% 276,746 2.4% \$2.42

**YTD** 2022 Jan.-Sep. 11,842,778 100.0% (9,453,828)2,388,950 20.2% (1,860,202)-15.7% 528,748 4.5% 69,218 597,966 5.0% 461,532 3.9% 393,157 3.3%

(a) EPS was calculated based on total Weighted -average Outstanding shares (thousand shares)

114,488

114,488

\$3.43


















#### **Balance Sheet Highlights (Consolidated)**

**Amount: NT\$ Thousand** 

Cash and cash equivalents

Accounts receivable
(Including the related parties)

Inventories

Property, plant and equipment

Total assets

Current liabilities

Non-current liabilities

2023.09.30	
1,558,624	13%
2,486,489	22%
3,096,572	26%
2,593,482	22%
11,715,784	100%
4,515,075	37%
1,554,512	14%
5,646,197	49%

2022.12.31 (Restated)		2022.09.3 (Restated	
1,690,474	13%	1,557,332	12%
2,884,097	22%	2,954,027	22%
3,816,596	29%	4,086,812	31%
2,793,096	21%	2,461,407	18%
13,174,581	100%	13,419,007	100%
5,190,715	39%	5,472,171	41%
2,159,076	17%	2,212,876	16%
5,824,790	44%	5,733,960	43%

Net Worth/Share(NT\$)

**Equity** 

Net worth per share was calculated based on total outstanding shares(thousand shares)

27.12	28.36	27.32
114,488	114,488	114,488



#### **Key Financial Ratios (Consolidated)**

AR Turnover(Days)

**Inventory Turnover(Days)** 

**AP Turnover(Days)** 

**Cash Conversion Cycle(Days)** 

**ROE**(annualized) (a)

**Current ratio** 

Fin.Debt(b)/Total Assets

2023.09.30
64
103
62
105
9.1%
163%
22%

2022.12.31	2022.09.30
(Restated)	(Restated)
65	66
113	111
<b>62</b>	66
116	111
10.5%	10.9%
166%	168%
26%	27%



<sup>(</sup>a)Annualized net income / Average total equity

<sup>(</sup>b)Fin.debt included long term and short term financial debts



## \_\_. Operation Outlook



#### **DFI Investment Distribution**




System (AEWIN)

#### Embedded(DFI)




















#### **DFI Medical Product Application**





- 7<sup>th</sup> Gen Intel Core Processor with Q170
- 4 DDR4 DIMM up to 64G8
- . Three display parts: VGA, DVI-D, DP++
- DP++ resolution up to 4096x2304 @ 60Hz . 1 PCle x16, 1 PCle x4, 1 PCl, 1 Mini PCle

Country: USA

Flexible & Easy Integration



Country: USA

- Intel Core/Intel Pentium Processor with Intel Q57
- 4 DDR3 DIMM up to 16GB
- 1 PCle x16, 1 PCle x4, 2 PCle x1, 3 PCl



(HM101-QM87D-4100E + customized chassis)

- 4th Gen Intel Core i3-4100E Dual Core processor
- · 7" LCD with projected capacitive multi-touch screen
- Multiple I/O ports: 2 GLAN, 2 COM, 5 USB, 1 DVI, 1 HDMI
- UL60601-1 compliant with high reliability

High Resolution Image & Video

Real-Time Connectivity

**ODM Service Capabilities** 

Country: USA



## 三. Q & A



## Thank you